Nitazoxanide is under clinical development by Genfit and currently in Phase I for Acute On Chronic Liver Failure (ACLF). According to GlobalData, Phase I drugs for Acute On Chronic Liver Failure (ACLF) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nitazoxanide LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nitazoxanide overview
Nitazoxanide is under development for the treatment of acute on chronic liver failure (ACLF), liver fibrosis in non-alcoholic steatohepatitis patients, cirrhosis and sepsis. The drug candidate acts by targeting stellate cells. It is administered through oral route. It is a repurposed drug. It was also under development for cirrhosis.
Genfit overview
Genfit is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include GFT505, NASH, TGFTX1 and Nitazoxanide (NTZ). Its TGFTX1 is a research program for neutrophilic asthma, chronic obstructive pulmonary disease and the asthma-COPD overlap syndrome (ACOS); NASH for treatment of liver diseases and NTZ for fibrotic diseases. Genfit develops diagnostic solutions in various therapeutic areas includes metabolic diseases, cholestatic liver diseases, inflammation and autoimmune diseases, and fibrotic diseases. The company’s research and development activities include multiple drug candidate research programs targeting novel mechanisms of action includes the inhibition of nuclear receptors ROR (a, ß, ?). It has presence in France and the US. Genfit is headquartered in Loos, France.
For a complete picture of Nitazoxanide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
